Q-omics provides the consensus-scored PPP1CB profile across patient tissues and cancer cell-line models. PPP1CB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PPP1CB is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, PPP1CB RNA expression shows 19,999 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, LIHC, and ACC as cancer lineages where PPP1CB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPP1CB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPP1CB survival associations across molecular data types. PPP1CB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPP1CB RNA expression–survival associations across cancer types. High PPP1CB expression shows unfavorable associations in ACC, LIHC, LGG and PAAD, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PPP1CB RNA expression.
This table summarizes PPP1CB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PPP1CB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPP1CB shows lower tumor expression in COAD, KICH and READ and higher tumor expression in LIHC, CHOL and HNSC. The LIHC box plot shows higher PPP1CB RNA expression in tumor versus normal tissue (log2 FC = +0.837, t-test p < 0.001).
This table shows molecular features associated with PPP1CB in patient tissues and cancer cell lines. In patient samples, PPP1CB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPP1CB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Leukemia.
